JP6118808B2 - ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物 - Google Patents

ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物 Download PDF

Info

Publication number
JP6118808B2
JP6118808B2 JP2014540047A JP2014540047A JP6118808B2 JP 6118808 B2 JP6118808 B2 JP 6118808B2 JP 2014540047 A JP2014540047 A JP 2014540047A JP 2014540047 A JP2014540047 A JP 2014540047A JP 6118808 B2 JP6118808 B2 JP 6118808B2
Authority
JP
Japan
Prior art keywords
mao
compound
moiety
cells
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014540047A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534227A (ja
JP2014534227A5 (enExample
Inventor
デイビッド エス． バスキン，
デイビッド エス． バスキン，
マーティン アルン シャープ，
マーティン アルン シャープ，
Original Assignee
ザ メソジスト ホスピタル リサーチ インスティテュート
ザ メソジスト ホスピタル リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ メソジスト ホスピタル リサーチ インスティテュート, ザ メソジスト ホスピタル リサーチ インスティテュート filed Critical ザ メソジスト ホスピタル リサーチ インスティテュート
Publication of JP2014534227A publication Critical patent/JP2014534227A/ja
Publication of JP2014534227A5 publication Critical patent/JP2014534227A5/ja
Application granted granted Critical
Publication of JP6118808B2 publication Critical patent/JP6118808B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2014540047A 2011-10-31 2012-10-31 ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物 Expired - Fee Related JP6118808B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161553854P 2011-10-31 2011-10-31
US61/553,854 2011-10-31
PCT/US2012/062850 WO2013151584A1 (en) 2011-10-31 2012-10-31 Compound comprising a mao targeting/ seeker moiety for treating human gliomas

Publications (3)

Publication Number Publication Date
JP2014534227A JP2014534227A (ja) 2014-12-18
JP2014534227A5 JP2014534227A5 (enExample) 2015-11-12
JP6118808B2 true JP6118808B2 (ja) 2017-04-19

Family

ID=47146760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014540047A Expired - Fee Related JP6118808B2 (ja) 2011-10-31 2012-10-31 ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物

Country Status (9)

Country Link
US (1) US10555936B2 (enExample)
EP (2) EP2804604A1 (enExample)
JP (1) JP6118808B2 (enExample)
KR (1) KR102110794B1 (enExample)
CN (1) CN104136026B (enExample)
AU (1) AU2012376221A1 (enExample)
CA (1) CA2887928A1 (enExample)
HK (1) HK1204547A1 (enExample)
WO (1) WO2013151584A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
CN104710433B (zh) * 2014-01-23 2016-08-17 南京友怡医药科技有限公司 苯丁酸氮芥衍生物、制备方法及应用
US10807944B2 (en) * 2014-04-04 2020-10-20 University Of Florida Research Foundation, Inc. HDAC inhibitor compounds and methods of treatment
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
JPH09501147A (ja) * 1993-06-07 1997-02-04 ザ・ウエルカム・ファウンデーション・リミテッド モノアミンオキシダーゼを使用する免疫反応性試薬
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5612329A (en) 1995-06-05 1997-03-18 University Of Maryland At Baltimore Diaziridinylpolyamine anti-cancer agents
WO1998022110A1 (en) * 1996-11-20 1998-05-28 Virginia Tech Intellectual Properties, Inc. Prodrugs for the selective inhibition of monoamine oxidase-b
KR20010102486A (ko) 1999-03-03 2001-11-15 데이비드 엠 모이어 알케닐- 및 알키닐-함유 메탈로프로테아제 저해제
US6727361B2 (en) 2000-11-07 2004-04-27 Symyx Technologies, Inc. Phosphino substituted pyridine amine ligands
US6946479B2 (en) 2002-11-09 2005-09-20 The Procter & Gamble Company N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
US7943586B2 (en) 2003-06-09 2011-05-17 The Trustees Of The University Of Pennsylvania Antineoplastic agents targeted via glut transporters
EP1758887A1 (en) * 2004-05-14 2007-03-07 Pfizer Products Incorporated Pyrimidine derivatives for the treatment of abnormal cell growth
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
GB0513297D0 (en) 2005-06-29 2005-08-03 Glaxo Group Ltd Novel compounds
US20070275944A1 (en) 2006-04-05 2007-11-29 The Board Of Trustees Operating Michigan State University Antioxidants and methods of their use
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
EP2141163A1 (de) * 2008-07-02 2010-01-06 Bayer Schering Pharma AG Substituierte Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
ES2668775T3 (es) * 2009-06-10 2018-05-22 Chugai Seiyaku Kabushiki Kaisha Compuestos tetracíclicos
US8293925B2 (en) * 2009-09-21 2012-10-23 Chemocentryx, Inc. Pyrrolidinone carboxamide derivatives
JP6118808B2 (ja) 2011-10-31 2017-04-19 ザ メソジスト ホスピタル リサーチ インスティテュート ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物

Also Published As

Publication number Publication date
US10555936B2 (en) 2020-02-11
JP2014534227A (ja) 2014-12-18
KR102110794B1 (ko) 2020-05-15
US20140323513A1 (en) 2014-10-30
WO2013151584A1 (en) 2013-10-10
EP2804604A1 (en) 2014-11-26
CN104136026A (zh) 2014-11-05
EP3815685A2 (en) 2021-05-05
CN104136026B (zh) 2018-03-02
HK1204547A1 (en) 2015-11-27
KR20140128943A (ko) 2014-11-06
CA2887928A1 (en) 2013-10-10
AU2012376221A1 (en) 2014-06-19
EP3815685A3 (en) 2021-10-13

Similar Documents

Publication Publication Date Title
JP5677296B2 (ja) グリオーマの治療のためのｃｄｋ阻害剤の使用
KR101938431B1 (ko) 뇌 종양의 치료를 위한 csf-1r 억제제
JP6193268B2 (ja) Ｃｄｋ８／ｃｄｋ１９選択的阻害剤、ならびに癌のための抗転移および化学防御の方法におけるそれらの使用
JP2020505396A (ja) 縮合ヘテロ−ヘテロ二環式化合物およびその使用方法
JP2020505395A (ja) 縮合ｎ−複素環式化合物およびその使用方法
US20130317101A1 (en) Singleton inhibitors of sumoylation enzymes and methods for their use
ES3002745T3 (en) Multifunctional inhibitors of mek/pi3k and mtor/mek/pi3k biological pathways and therapeutic methods using the same
Li et al. Discovery of the polyamine conjugate with benzo [cd] indol-2 (1 H)-one as a lysosome-targeted antimetastatic agent
WO2011002852A2 (en) Pro-drug complexes and related methods of use
KR20190025733A (ko) 원발성 호르몬 저항성 자궁내막암 및 유방암 치료 방법 및 약학적 조성물
JP2019501225A (ja) Ｂ細胞リンパ腫２（ｂｃｌ−２）及び関連タンパク質の阻害
JP2014534227A (ja) ヒトグリオームを治療するためのｍａｏ標的化／探索部分を含む化合物
US20100316655A1 (en) Compounds with mdr1-inverse activity
Chen et al. A Prostate-Specific Membrane Antigen-Targeting Small Molecule–Drug Conjugate Strategy to Overcome the Hematological Toxicity of Olaparib
US20180360843A1 (en) Mao inhibitors and their conjugates as therapeutics for the treatment of brain cancer
US20120329767A1 (en) Methods and Compositions for Treating Cancer
US20130131156A1 (en) Cancer Treatment with Wortmannin Analogs
Sharpe et al. PAM-OBG: A monoamine oxidase B specific prodrug that inhibits MGMT and generates DNA interstrand crosslinks, potentiating temozolomide and chemoradiation therapy in intracranial glioblastoma
US20200030275A1 (en) Enhancer of photodynamic effect in ala-pdt or ala-pdd
US20240173418A1 (en) Cyclic dinucleotide conjugates and related methods of use thereof
JP2026507092A (ja) 健康状態の治療のための小分子を作製および使用するための組成物および方法
WO2026065490A1 (zh) Mitoxantrone在制备药物中的用途、治疗或预防神经内分泌肿瘤的方法

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150918

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150918

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160630

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170327

R150 Certificate of patent or registration of utility model

Ref document number: 6118808

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees